What to Know About Tysabri and PML Risk

Latest update (2026-07)

From General Health Awareness to Specific Risk Assessment

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This page reviews the established risk factors and the boundaries of current evidence, drawing on decades of pharmaceutical safety research to help you understand what is known and what remains uncertain.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Massachusetts who have developed PML after Tysabri exposure, understanding the medical evidence and legal time limits for filing a claim is critical. The prescribing information for Tysabri contains a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and the expected benefit must be weighed against the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

Clinically, PML presents with progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination problems. Diagnosis relies on MRI findings and detection of JC virus DNA in cerebrospinal fluid. The label instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI dosing immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has been reported even after discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of stopping treatment. Therefore, monitoring should continue for at least six months following discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes. This immunosuppressive effect is the biological basis for the increased PML risk.

Adequacy of Warnings and Settlement Considerations

Regarding the adequacy of warnings, the FDA-approved label includes a boxed warning and a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, affected patients may argue that the warnings were insufficient to prevent harm, particularly if risk factors were not adequately communicated or if monitoring protocols were not followed. Settlement considerations for patients who developed PML often involve evaluating whether the treating physician and manufacturer provided appropriate risk information and whether earlier detection could have altered outcomes. The timeline between Tysabri exposure and documented PML harm is variable but typically occurs after prolonged treatment. The label identifies longer treatment duration, especially beyond two years, as a key risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML can develop months to years after starting therapy, and cases have been reported after discontinuation, complicating the determination of when the injury occurred.

Massachusetts Statute of Limitations for Tysabri PML Claims

In Massachusetts, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, this discovery date may be the date of diagnosis or when symptoms first appeared. Given the latency of PML and the possibility of delayed diagnosis, patients should promptly consult with legal counsel to assess their specific timeline. The settlement process for Tysabri-related PML claims may involve demonstrating that the drug caused the injury and that the warnings were inadequate. Evidence of risk factor assessment, monitoring compliance, and the timing of symptom onset will be central to any claim. In summary, Tysabri carries a known risk of PML, with specific risk factors and a requirement for close monitoring. Massachusetts patients affected by PML must be aware of the three-year statute of limitations from discovery of the injury. Legal and medical evaluation should occur as soon as possible after diagnosis to preserve the right to seek compensation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for a Tysabri PML claim in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, this discovery date is typically the date of diagnosis or when symptoms first appeared. It is crucial to consult with legal counsel promptly to ensure your claim is filed within this timeframe.

What are the risk factors for developing PML from Tysabri?

The prescribing information for Tysabri identifies three specific risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and the expected benefit must be weighed against the PML risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

Related Articles

References

  1. Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Time is limited. Request your evaluation today.

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.